Basket cover image
16 handpicked stocks

Smart Shopper Portfolio

Invest in brands you already know and trust that stock your shelves at home. These aren't just familiar names—they're companies that financial experts have given their strongest vote of confidence with "Strong Buy" ratings.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+6

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at June 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

LCUT

LIFETIME BRANDS INC

LCUT

Current price

$3.81

Provides exposure to household goods with strong brand recognition and a favorable analyst rating.

PG

Procter & Gamble Company, The

PG

Current price

$158.40

A quintessential consumer staples company with a portfolio of globally recognized brands, fitting the familiar-brand criterion.

CL

Colgate-Palmolive Co.

CL

Current price

$85.85

A classic consumer defensive stock with a portfolio of essential daily-use products and a strong 'Buy' analyst consensus.

About This Group of Stocks

1

Our Expert Thinking

We've built this collection around everyday brands with strong consumer loyalty. These companies make the products you regularly use and trust—from food and beverages to household essentials—creating a foundation of familiarity for your investment approach.

2

What You Need to Know

This portfolio combines the comfort of investing in recognizable brands with professional validation. Every company here has earned a "Strong Buy" rating from financial analysts, providing an extra layer of confidence beyond just brand recognition.

3

Why These Stocks

These companies benefit from consistent consumer demand, helping them weather economic uncertainty. When people need everyday products regardless of market conditions, these businesses can maintain steady revenue streams, potentially offering more resilient performance.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+61.88%

Group Performance Snapshot

61.88%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 61.88% over the next year.

15 of 16

Stocks Rated Buy by Analysts

15 of 16 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🛒

Shop Where You Invest

There's something satisfying about investing in the very products you use daily. This portfolio lets you put your money behind the brands you already trust and buy regularly.

🔍

Expert-Approved Only

Every company here has earned a coveted "Strong Buy" rating from financial analysts. It's like having professional shoppers select only the best brands for your investment cart.

💡

Recession-Resistant Potential

When economic times get tough, people still need their everyday essentials. These companies provide products that consumers buy regardless of what's happening in the broader economy.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.